###begin article-title 0
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 131 134 131 134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">10 </bold>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 292 297 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Ovarian carcinomas from 30 BRCA1 germ-line carriers of two distinct high penetrant founder mutations, 20 carrying the 1675delA and 10 the 1135insA, and 100 sporadic cases were characterized for somatic mutations in the TP53 gene. We analyzed differences in relation to BRCA1 germline status, TP53 status, survival and age at diagnosis, as previous studies have not been conclusive.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
DNA was extracted from paraffin embedded formalin fixed tissues for the familial cases, and from fresh frozen specimen from the sporadic cases. All cases were treated at our hospital according to protocol. Mutation analyses of exon 2 - 11 were performed using TTGE, followed by sequencing.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Survival rates for BRCA1-familial cases with TP53 mutations were not significantly lower than for familial cases without TP53 mutations (p = 0.25, RR = 1.64, 95% CI [0.71-3.78]). Median age at diagnosis for sporadic (59 years) and familial (49 years) cases differed significantly (p < 0.001) with or without TP53 mutations. Age at diagnosis between the two types of familial carriers were not significantly different, with median age of 47 for 1675delA and 52.5 for 1135insA carriers (p = 0.245). For cases >/=50 years at diagnosis, a trend toward longer survival for sporadic over familial cases was observed (p = 0.08). The opposite trend was observed for cases <50 years at diagnosis.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 656 662 654 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 850 856 848 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
There do not seem to be a protective advantage for familial BRCA1 carriers without TP53 mutations over familial cases with TP53 mutations. However, there seem to be a trend towards initial advantage in survival for familial cases compared to sporadic cases diagnosed before the age of 50 both with and without TP53 mutations. However, this trend diminishes over time and for cases diagnosed >/=50 years the sporadic cases show a trend towards an advantage in survival over familial cases. Although this data set is small, if confirmed, this may be a link in the evidence that the differences in ovarian cancer survival reported, are not due to the type of BRCA1 mutation, but may be secondary to genetic factors shared. This may have clinical implications for follow-up such as prophylactic surgery within carriers of the two most frequent Norwegian BRCA1 founder mutations.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 95 98 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 71 76 <span type="species:ncbi:9606">women</span>
###xml 120 125 <span type="species:ncbi:9606">women</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
Ovarian cancer is one of the leading causes of cancer-related death in women today. It is the 4th most common cancer in women in Norway and accounts for 5 - 6% of all cancers [1,2]. Mean age at diagnosis for sporadic cases have been reported to 62.3 years [3], and in Norway to 65 years. Age-standardized incidence rates were 13.5 pr 100.000, and close to 40% of the patients is achieving 5-year survival according to The Norwegian Cancer Registry (OVANOR 1991 - 1996).
###end p 11
###begin p 12
###xml 148 154 148 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 702 708 702 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 777 778 777 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 931 937 931 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1000 1006 1000 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 674 682 <span type="species:ncbi:9606">patients</span>
Almost 10% of epithelial ovarian cancer cases are associated with dominant genetic predisposition, in most cases (80 - 90%), linked to mutations in BRCA1 or BRCA2 [4-6]. Mean age at diagnosis for these inherited cases have been reported to be from 49 to 54.3 years [3,7]. The penetrance of the disease in mutation carriers varies, and has been reported to be from 27 - 80% [8-10]. It should be noted that both the incidence rate for hereditary cases and the penetrance of the disease may differ depending on geographic and ethnic origin [11]. The survival rate may also vary depending on type and localization of the mutation. Some studies have reported that ovarian cancer patients carrying germ-line BRCA1 mutations have an enhanced survival rate compared to sporadic cases [3,12-14]. Other studies demonstrated only an initial survival advantage that disappeared with time, and concluded that no enhanced survival rates follows BRCA1 dysfunction [15-17]. These studies predict a survival rate for BRCA1 familial ovarian cancer that is equal to or higher than non-familial cases.
###end p 12
###begin p 13
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Both the penetrance estimates and the survival rates are based on studies in populations with strong founder effects, and may therefore be biased. The type of mutation in the BRCA1 gene may affect the timing of the diagnosis of the disease, the response to environmental exposure causing DNA damage, the efficiency of DNA repair, and the frequency of somatic mutations developing in the tumor. These factors may in turn affect the survival rate.
###end p 13
###begin p 14
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 290 295 290 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 381 387 381 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 633 638 633 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 662 674 662 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/BRCA2 </italic>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
Mutations in the TP53 tumor suppressor gene are the most common genetic alteration in human tumors and have been suggested as a molecular marker for prognosis. TP53 encodes a nuclear phosphoprotein located at chromosome region 17p13 involved in cell cycle arrest and DNA repair and somatic TP53 mutations are known to associate with familial ovarian cancer. In ovarian tumors from BRCA1 mutation carriers, somatic TP53 mutations are found in 60 - 80% of the cases [18-22]. Thirty to 50% of all ovarian cancers have been reported to harbor a TP53 mutation [18-20,23,24]. Further, in 30 - 85% of the sporadic ovarian carcinomas both a TP53 mutations and a somatic BRCA1/BRCA2 mutation have been found [18,20,25].
###end p 14
###begin p 15
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53</italic>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
These findings implicate that TP53 and BRCA1 directly interacts and may play an important role in DNA repair processes and tumor suppression [26,27]. However, despite the high frequency of mutations in the tumor suppressor gene TP53, there are several reports concluding that TP53 is not a good predictor of prognosis in sporadic ovarian cancer patients [24,28,29].
###end p 15
###begin p 16
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 249 255 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 695 701 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 585 590 <span type="species:ncbi:9606">women</span>
We have previously reported two Norwegian BRCA1 founder mutations; 1135insA [30] and 1675delA [11]. Carriers of these mutations show almost the same penetrance for ovarian- and breast cancer and the penetrance is also high compared to most reported BRCA1 mutation carriers. By age 50, 48% of mutation carriers had experienced breast- and/or ovarian cancer. Mean age of ovarian cancer diagnosis was ~55 years [10]. Three per cent of all Norwegian ovarian cancers are caused by either of the two founder mutations [31]. As a result of a clinical follow-up program for early diagnosis in women from breast-ovarian cancer kindreds, these two mutations may account for more than half of those with a BRCA1 mutation in Norway. The histopathological characteristics of both breast and ovarian cancer indicated an unfavorable prognosis in these mutation carriers [32].
###end p 16
###begin p 17
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 263 269 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 309 315 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 343 348 343 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
In the present study, we have screened epithelial ovarian tumors from 30 familial cases and 100 sporadic cases for somatic mutations in the TP53 gene. The cancer treatment was according to our hospital protocol. The familial cases consisted of one group with the BRCA1 1135insA mutation and the other had the BRCA1 1675delA mutation [10]. The TP53 mutation status was correlated to survival, age at diagnosis and histopathological features.
###end p 17
###begin title 18
Materials
###end title 18
###begin p 19
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1258 1261 1258 1261 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 170 178 <span type="species:ncbi:9606">patients</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 910 917 <span type="species:ncbi:9606">patient</span>
Formalin fixed and paraffin embedded ovarian cancer tissue from 30 BRCA1 germ line mutation carriers were collected and used for DNA extraction. Of the familial cases 20 patients carried the 1675delA mutation and another 10 patients the 1135insA mutation, which is a representative distribution between the two mutations in the Norwegian population. The BRCA1 carriers were from families with at least two first-degree relatives, or second-degree relatives through male, with ovarian cancer and/or breast cancer under age 60. All cases were sampled from pedigree regardless of survival status, as ovarian cancer treatment is centralized to our hospital. Analysis of fresh frozen specimen of tumor DNA from the 100 sporadic cases sampled from 1992-2003, included in this study has previously been reported [29]. Both groups were diagnosed and treated at the Norwegian Radium Hospital according to protocol. The patient characteristics are shown in Table 1. All tumors were reviewed at our department of pathology, the familial tumors by our team pathologist, and were classified and graded according to the World Health Organization (WHO) criteria. Follow-up time for each case was calculated from the date of diagnosis up to date of death or end of study (15th April, 2004).
###end p 19
###begin title 20
Methods
###end title 20
###begin title 21
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
DNA extraction and TP53 mutation analysis
###end title 21
###begin p 22
###xml 164 166 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
DNA was manually extracted from paraffin-embedded tissue sections of tumor material using 5 sections of 10 mu. A modification of the procedure described by Miller [33] was used. The modification included using as much as possible of the top water layer of the 700 ml DNA/lysis buffer and 1 ml phenol/chloroform/water mix, and repeating the extraction step once. The protocol was optimized to give high yield of good quality DNA.
###end p 22
###begin p 23
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Mutation analyses of exons 2-11 of the TP53 gene in the 30 cases with BRCA1 germ line mutations were performed by TTGE followed by sequencing. Primers, PCR conditions and gel running conditions were as described elsewhere [34]. Samples with aberrantly migrating bands on TTGE were isolated, submitted to a new PCR and sequenced. Analysis of the fresh frozen specimen of tumor DNA from the 100 sporadic cases has previously been reported [29].
###end p 23
###begin title 24
Statistical analyses
###end title 24
###begin p 25
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 364 368 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
In univariate analyses, a log rank test have been used to investigate the effect of age at diagnosis, BRCA1 and TP53 mutations on the survival rate. In multivariate analyses, Cox proportional hazards regression analysis was used. Hazard ratios (HR's) are given with 95% confidence intervals (CI's). Statistical significance rates were set at 0.05. The software SAS(R) version 8.2 was used for statistical analyses.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
TP53 characterizations and novel mutations
###end title 27
###begin p 28
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Nineteen of the 30 ovarian carcinomas showed one or more aberrant migrating bands on TTGE in one or more exons and was sequenced (Table 2). A total of 21 sequence changes were detected. Two cases had two different TP53 sequence changes in their tumors, one being a silent mutation. Nine mutations were missense mutations, four nonsense, three were silent sequence changes (not previously reported as polymorphisms) and two were intronic sequence changes of unknown function.
###end p 28
###begin p 29
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 459 465 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 566 572 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 744 749 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 828 833 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1029 1034 1029 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1193 1198 1193 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1444 1449 1444 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 1527 1529 1527 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
The frequency of transitions vs. transversion in this hereditary cohort (85.7% and 14.3%) was also quite similar to that reported in the IARC database for sporadic cases (88% and 12%), but differed slightly from the sporadic cases in this study (76.4% and 23.6%). The frequency of mutations likely to cause protein alteration were 68.0% (68/100) for the sporadic cases and 53.3%(16/30) for the familial cases. The TP53 mutation frequency in the two different BRCA1 carriers differed slightly with 11/20 (55.0%) in the BRCA1 1675delA carriers and 5/10 (50.0%) in the BRCA1 1135insA carriers. The 1675delA carriers had 7.7% transversions and 92.3% transitions while the 1135insA carriers had 12.5% transversion and 82.5% transitions. Four of the TP53 mutations were novel and not previously reported in ovarian cancer in the IARC TP53 Database [35] or the SOUSSI database. These mutations affected codon 205 (tyr>ser), 260 (ser>ser), 267 (arg>gln) and 293 (gly>arg). All mutations detected resided in exons 5-8. When comparing the TP53 mutation spectrum in these familial cases with that of ovarian cancers cases reported in the IARC database and to the 100 sporadic ovarian cancer cases with a TP53 mutation, no obvious differences were seen either with respect to exon distribution or codon wise (data not shown), although a slightly lower frequency of mutations in exon 5 and a slightly higher in exon 8 were seen in the hereditary cases. The TP53 mutations in the 100 sporadic cases used in this study is reported elsewhere [29].
###end p 29
###begin title 30
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Age at diagnosis, survival, BRCA1 and TP53 status
###end title 30
###begin p 31
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Median age at diagnosis among sporadic cases and familial cases that carried 1675delA or 1135insA mutations is presented in Table 1. As expected, the familial cases are diagnosed earlier in life than sporadic cases (p < 0.001). The difference in median age of onset between the 1135insA and 1675delA mutation carriers was not significant (p = 0.245).
###end p 31
###begin p 32
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 251 256 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 354 360 352 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 371 376 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 465 471 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
In the univariate analysis of the combined group, neither BRCA1 status nor age at diagnosis was significantly associated to survival (p = 0.87 and p = 0.50 for BRCA1 status and age at diagnosis (categorized into < 50 and >/= 50 years), respectively). TP53 mutation did not significantly reduce the survival rates (p = 0.35). Notably, interaction between BRCA1 status and TP53 status was borderline significant (test for interaction: p = 0.06) while the one between BRCA1 status and age at diagnosis was statistically significant (test for interaction: p = 0.05). We further analyzed these factors adjusted for tumor grade, however, results did not substantially change (test interaction: p = 0.04 and p = 0.05 for BRCA1*TP53 and BRCA1*age at diagnosis, respectively).
###end p 32
###begin p 33
###xml 598 603 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 676 677 674 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 714 719 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 754 760 752 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
No association between age at diagnosis and survival time was found among sporadic cases (p = 0.88). Familial cases with late age at diagnosis (>/=50 years) had a slightly higher risk of dying than the cases with an early age at diagnosis, however the association did not reach significance, possibly due to a lack of statistical power (RR = 1.65, 95% CI [0.79-3.43], p = 0.14). Among cases diagnosed at age 50 years or more, familial cases had a trend towards a higher risk of dying than sporadic cases (RR = 1.75, 95% CI [0.93-3.30], p = 0.08). After adjustment for the effect of tumor grade and TP53 status (RR = 1.80, 95% CI [0.94-3.43], p = 0.08) (data not shown). Table 3 shows the risk ratios associated to TP53 mutations after stratification for BRCA1 status.
###end p 33
###begin p 34
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
There was no significant difference in survival observed among TP53 mutations carriers compared to non-TP53 mutations carriers, neither for the familial nor the sporadic cases (Log-rank test for TP53 in familial cases: p = 0.25 and log-rank test for TP53 in sporadic cases: p = 0.88) (Table 3).
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Some studies have reported an enhanced survival for BRCA1 carriers with ovarian cancer compared to sporadic cases [12-14,36,37], but these studies have not taken TP53 status in the tumors in to consideration. Other studies in which TP53 status have been included concludes that there is no difference in survival [16].
###end p 36
###begin p 37
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Our results do not show an enhanced survival rate for familial cases compared to sporadic cases, even after adjustment for TP53 status when all age groups were included. Further, no significant difference in survival rates was observed between the familial cases with and without TP53 mutations (Table 3).
###end p 37
###begin p 38
###xml 14 21 14 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">do not </bold>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
These results do not support earlier observations regarding the importance of the p53/BRCA1 interaction on cell proliferation and ovarian carcinogenesis. Most penetrance estimates and survival rates are based on studies in populations with strong founder effects, and may therefore be biased [15-17,38]. Two Ashkenazi founder mutations occur in BRCA1 185delAG and 5382insC (carrier frequencies of 0.9% and 0.13%), with mean age at diagnosis 54 years. How the type of mutation in the BRCA1 gene affects survival, age at diagnosis of the disease, the response to environmental exposure causing DNA damage, and the efficiency of DNA repair, is not clarified. Heterozygote advantage or an increase in biological fitness conferred on carriers of a disease causing mutation (like BRCA1?), often a resistance to certain infections that were common in times past, can cause an increase in allele frequency [39]. Genetic factors with impact on survival and age at onset of disease, to after childbearing age, would be preferential.
###end p 38
###begin p 39
###xml 428 434 428 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
The trend for an increased survival in favour of the early age at onset in familial cases compared to late age at onset in familial cases may be attributed to younger patients having greater physical strength, less somatic mutations, and manage illness better than older patients. On the other hand, one might also expect this trend in sporadic cases, which was not the case. One limitation of our study is the small numbers of BRCA1 carriers. In our study, the statistical power to detect BRCA1 effect was 76%.
###end p 39
###begin p 40
###xml 110 116 110 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Consequently, our findings should be confirmed in larger studies. The conflicting literature on the impact of BRCA1 mutation status on ovarian cancer survival should promote additional studies from different ethnic populations, and thereby allow investigators to study whether or not there is a survival benefit due to BRCA1 mutation, or may be secondary to other common inherited genetic factors, which may be shared in ethnic or geographic isolated populations.
###end p 40
###begin p 41
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 416 422 416 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 497 503 497 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 632 638 632 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 661 666 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 736 741 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 766 772 766 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 860 865 860 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 937 943 937 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1122 1128 1122 1128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1240 1246 1240 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1268 1270 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1271 1273 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1339 1340 1339 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
Alterations in the TP53 gene have been shown to affect breast cancer survival and in particular patients with mutations in the zinc-binding domains have poor survival [40]. In sporadic ovarian carcinoma several studies reports that no or little effect of TP53 mutations have been seen [17,24,28], which is similar to the results reported here. TP53 alterations are also suggested to alter ovarian cancer survival in BRCA1 germ line patients [13,14], while other groups concludes with a failure of BRCA1 dysfunction to alter ovarian cancer survival [16]. It should also be noted that a considerable fraction (60-80%) of all familial BRCA1 ovarian cancers harbor TP53 mutations [18,19,21,22]. Only a few studies have reported analysis of TP53 mutations in relation to BRCA1 associated ovarian cancer [20,41]. The present study is the first investigating somatic TP53 mutations in ovarian tumors from carries of two distinct high penetrant BRCA1 germ-line mutations, relating it to survival and age at diagnosis of disease and compares it to sporadic cases. We have previously studied the distribution in age at diagnosis in BRCA1 carriers and non-carriers as a part of a cohort study. Three percent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA [31,42], with a distribution similar to that found in this study (Table 1). Further, Bjorge et al. [43] found that 87.0% of Norwegian sporadic ovarian cancers was papillary serous adenocarcinoma, an aggressive histo-prognostic factor.
###end p 41
###begin p 42
###xml 201 207 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 466 471 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 935 940 935 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Eigthy percent of both familial and sporadic ovarian cancer cases in this study were papillary serous adenocarcinoma. Questions need to be addressed concerning the clinical effects of mutations in the BRCA1 gene, why some mutation carriers develop breast cancer, others develop ovarian cancer, and some develop both. We do not know whether the cancers occurring in mutation carriers are significantly different from those occurring in non carriers. The frequency of TP53 mutations in the familial cases altering the protein was 53.3%, which is somewhat higher than other studies of familial BRCA1 ovarian cancer (31-50%) [18-22,24,25]. Although the number of familial cases in this study is limited, a slightly higher frequency of mutations was found in exon 8 and a lower frequency in exon 5 compared to sporadic cases in the IARC database. The same tendency has been reported by others [20]. However, a non-significant difference in TP53 mutation frequency was observed between the familial and sporadic cases in this study.
###end p 42
###begin p 43
###xml 651 657 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
Of the novel mutations found in the familial cohort the codon 205 mutation has previously been reported in several other tumors like head and neck SCC as well as breast- and colorectal carcinoma. The amino acid change in codon 255 and 293 are only reported once, in oesophageal SCC and bladder cancer, respectively. The silent codon 260 mutation are reported in two different cancer tissues; lung (SCLC) and colorectal carcinoma. Environmental exposure, both external and internal, is known to influence the spectrum of mutations. Whether hormonal disturbance may affect the mutation rate and spectrum is not known, but if so, it may be expected that BRCA1 carriers are more sensitive to such exposure.
###end p 43
###begin title 44
Conclusion
###end title 44
###begin p 45
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Interestingly, no difference in survival was observed between TP53 mutation carriers among the familial carries or among the sporadic cases (Table 3). Further, we did not find an overall difference in survival between familial BRCA1 carriers and sporadic epithelial ovarian cancer cases, even after adjustment for TP53 status. For cases diagnosed over the age 50 there was a trend toward higher survival for sporadic cases.
###end p 45
###begin title 46
List of abbreviations
###end title 46
###begin p 47
TTGE; temporal temperature gradient gel electrophoresis; PCR, polymerase chain reaction; FIGO, International Federation of Gynaecology and Obstetrics. RR; risk ratio.
###end p 47
###begin title 48
Competing interests
###end title 48
###begin p 49
The author(s) declare that they have no competing interests.
###end p 49
###begin title 50
Authors' contributions
###end title 50
###begin p 51
PK participated in the design of the study, carried out the molecular genetic studies, sequence alignment and drafted the manuscript. YW participated in screening of the sporadic cases and sequence alignment. VD performed the statistical analyses. GK performed clinical updates of sporadic cases.
###end p 51
###begin p 52
JMN evaluated pathology sections of sporadic and familial cases. ALBD conceived the study, participated in its design and helped draft the manuscript. AD conceived the study, performed clinical dates of the familial cases and helped draft the manuscript. All authors read and approved the final manuscript.
###end p 52
###begin title 53
Pre-publication history
###end title 53
###begin p 54
The pre-publication history for this paper can be accessed here:
###end p 54
###begin p 55

###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
Pedro Kringen is a research fellow of The Norwegian Cancer Society. Guro Elisabeth Lind is acknowledged for working out the optimal condition for DNA extraction from paraffin embedded tissues. We thank Sigrid Lystad and Phuong Vu for providing excellent technical assistance.
###end p 57
###begin p 58
This work was supported by grants from The Norwegian Cancer Society and The Norwegian Research Council.
###end p 58
###begin article-title 59
Cancer in Norway 1998.
###end article-title 59
###begin article-title 60
Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries
###end article-title 60
###begin article-title 61
Differences between hereditary and sporadic ovarian cancer
###end article-title 61
###begin article-title 62
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
###end article-title 62
###begin article-title 63
Identification of the breast cancer susceptibility gene BRCA2
###end article-title 63
###begin article-title 64
Molecular genetics of hereditary ovarian cancer
###end article-title 64
###begin article-title 65
Hereditary ovarian cancer. Heterogeneity in age at onset
###end article-title 65
###begin article-title 66
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence
###end article-title 66
###begin article-title 67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
###end article-title 67
###begin article-title 68
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer
###end article-title 68
###begin article-title 69
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
###end article-title 69
###begin article-title 70
###xml 56 61 <span type="species:ncbi:9606">women</span>
Clinical and pathological features of ovarian cancer in women with germ- line mutations of BRCA1
###end article-title 70
###begin article-title 71
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors
###end article-title 71
###begin article-title 72
###xml 21 26 <span type="species:ncbi:9606">women</span>
Improved survival in women with BRCA-associated ovarian carcinoma
###end article-title 72
###begin article-title 73
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden
###end article-title 73
###begin article-title 74
Failure of BRCA1 dysfunction to alter ovarian cancer survival
###end article-title 74
###begin article-title 75
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
###end article-title 75
###begin article-title 76
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours
###end article-title 76
###begin article-title 77
Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors
###end article-title 77
###begin article-title 78
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer
###end article-title 78
###begin article-title 79
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers
###end article-title 79
###begin article-title 80
BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis
###end article-title 80
###begin article-title 81
###xml 21 26 <span type="species:ncbi:9606">human</span>
p53 gene mutation in human borderline epithelial ovarian tumors
###end article-title 81
###begin article-title 82
P53 mutation does not affect prognosis in ovarian epithelial malignancies
###end article-title 82
###begin article-title 83
Expression of p53 in epithelial ovarian cancer
###end article-title 83
###begin article-title 84
###xml 68 72 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
###end article-title 84
###begin article-title 85
###xml 100 105 <span type="species:ncbi:9606">human</span>
Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors
###end article-title 85
###begin article-title 86
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
###end article-title 86
###begin article-title 87
###xml 137 145 <span type="species:ncbi:9606">patients</span>
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
###end article-title 87
###begin article-title 88
A common BRCA1 mutation in Norwegian breast and ovarian cancer families?
###end article-title 88
###begin article-title 89
Three per cent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA
###end article-title 89
###begin article-title 90
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations
###end article-title 90
###begin article-title 91
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 91
###begin article-title 92
Mutation Screening of the TP53 Gene by Temporal Temperature Gradient Gel Electrophoresis
###end article-title 92
###begin article-title 93
The IARC TP53 database: new online mutation analysis and recommendations to users
###end article-title 93
###begin article-title 94
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations
###end article-title 94
###begin article-title 95
Survival analysis in familial ovarian cancer, a case control study
###end article-title 95
###begin article-title 96
A common BRCA1 mutation in the Ashkenazim
###end article-title 96
###begin article-title 97
Defective DNA Mismatch Repair in Acute Myeloid Leukemia/Myelodysplastic Syndrome After Organ Transplantation
###end article-title 97
###begin article-title 98
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains
###end article-title 98
###begin article-title 99
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer [see comments]
###end article-title 99
###begin article-title 100
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital.
###end article-title 100
###begin article-title 101
###xml 13 21 <span type="species:ncbi:9606">patients</span>
Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993
###end article-title 101
###begin title 102
Figures and Tables
###end title 102
###begin p 103
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end p 103
###begin p 104
All tumors are epithelial adenocarcinomas
###end p 104
###begin p 105
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
TP53 mutations, survival and histopathological features for each case.
###end p 105
###begin p 106
###xml 112 115 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
a: 1 = 1675delA and 2 = 1135insA. b: undifferentiated (4). c: all patients were followed until diseased or to 15th April, 2004. d: alive without cancer (1), alive with cancer (2), and dead by cancer (3). e: two different mutations detected in sample.
###end p 106
###begin p 107
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
Hazard risk of TP53 mutations on familial and sporadic ovarian cancer cases.
###end p 107

